108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
乌帕替尼治疗 1 型糖尿病患者获得性反应性穿刺性胶原病的疗效：1 例病例报告及文献综述
Authors Chen J, Deng T , Li M, Lian C
Received 25 June 2025
Accepted for publication 17 September 2025
Published 29 September 2025 Volume 2025:18 Pages 2489—2494
DOI https://doi.org/10.2147/CCID.S549157
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Michela Starace
Jiehui Chen,1,2 Tao Deng,1,2 Maoying Li,2,3 Cuihong Lian2
1Shenzhen University, Shenzhen, Guangdong, People’s Republic of China; 2Department of Dermatology and Venereology, Shenzhen Second People’s Hospital, Shenzhen, Guangdong, People’s Republic of China; 3Guangxi University of Chinese Medicine, Nanning, Guangxi, People’s Republic of China
Correspondence: Cuihong Lian, Department of Dermatology and Venereology, Shenzhen Second People’s Hospital, No. 3002, Sungang West Road, Huafu Sub-Street, Futian District, Shenzhen, Guangdong, People’s Republic of China, Email liancuihong@email.szu.edu.cn
Abstract: Acquired reactive perforating collagenosis (ARPC) is a rare skin condition characterized by collagen loss through the epidermis. We report the first clinical use of the JAK inhibitor upadacitinib for treating ARPC in a 32-year-old woman with a 17-year history of type 1 diabetes, whose persistent pruritic lesions responded poorly to conventional treatments. The patient started a daily regimen of 15 mg upadacitinib and showed a rapid response within 2 weeks, with significant lesion flattening and no new eruptions. By week 4, her pruritus was fully resolved. By week 16, she transitioned to an every-other-day dosing schedule without adverse effects. This article reviews existing literature on JAK inhibitors in ARPC treatment, indicating favorable outcomes. However, given the characteristics of ARPC, sustained maintenance therapy with JAK inhibitors may be necessary. We also explore the potential role of the JAK-STAT signaling pathway in the pathogenesis of ARPC associated with different types of diabetes, suggesting that JAK inhibitors may offer new therapeutic options for diabetic patients with ARPC. The limitations of this article include a small sample size and a lack of cost-effectiveness analysis. Therefore, larger-scale studies are needed to validate the efficacy and safety of JAK inhibitors in the treatment of ARPC and to further investigate clinical differences among patients with various forms of diabetes complicated by ARPC.
Keywords: upadacitinib, treatment, acquired reactive perforating collagenosis, type 1 diabetes
1Shenzhen University, Shenzhen, Guangdong, People’s Republic of China; 2Department of Dermatology and Venereology, Shenzhen Second People’s Hospital, Shenzhen, Guangdong, People’s Republic of China; 3Guangxi University of Chinese Medicine, Nanning, Guangxi, People’s Republic of China
Correspondence: Cuihong Lian, Department of Dermatology and Venereology, Shenzhen Second People’s Hospital, No. 3002, Sungang West Road, Huafu Sub-Street, Futian District, Shenzhen, Guangdong, People’s Republic of China, Email liancuihong@email.szu.edu.cn
Abstract: Acquired reactive perforating collagenosis (ARPC) is a rare skin condition characterized by collagen loss through the epidermis. We report the first clinical use of the JAK inhibitor upadacitinib for treating ARPC in a 32-year-old woman with a 17-year history of type 1 diabetes, whose persistent pruritic lesions responded poorly to conventional treatments. The patient started a daily regimen of 15 mg upadacitinib and showed a rapid response within 2 weeks, with significant lesion flattening and no new eruptions. By week 4, her pruritus was fully resolved. By week 16, she transitioned to an every-other-day dosing schedule without adverse effects. This article reviews existing literature on JAK inhibitors in ARPC treatment, indicating favorable outcomes. However, given the characteristics of ARPC, sustained maintenance therapy with JAK inhibitors may be necessary. We also explore the potential role of the JAK-STAT signaling pathway in the pathogenesis of ARPC associated with different types of diabetes, suggesting that JAK inhibitors may offer new therapeutic options for diabetic patients with ARPC. The limitations of this article include a small sample size and a lack of cost-effectiveness analysis. Therefore, larger-scale studies are needed to validate the efficacy and safety of JAK inhibitors in the treatment of ARPC and to further investigate clinical differences among patients with various forms of diabetes complicated by ARPC.
Keywords: upadacitinib, treatment, acquired reactive perforating collagenosis, type 1 diabetes